O'Sullivan Miriam 4

What Happened

• Miriam O'Sullivan, Senior Vice President & Chief Human Resources Officer at Boston Scientific, had restricted stock units (RSUs) convert to common shares on Feb 13, Feb 14 and Feb 16, 2026. A total of 2,702 shares were issued to her (588 + 1,124 + 990). To satisfy tax withholding, 820 of those shares were surrendered (200 + 329 + 291) at a withholding price of $74.73 per share, totaling $61,278. Net shares delivered to her after withholding: 1,882.
• These were not open-market purchases or voluntary sales — they are compensation-related vesting/conversion events (derivative exercise/settlement with shares withheld for taxes).

Key Details

• Transaction dates and codes: Feb 13, 2026 (M = conversion/exercise; F = tax withholding), Feb 14, 2026 (M/F), Feb 16, 2026 (M/F).
• Price used for withholding: $74.73 per share. Withheld/share-surrender proceeds reported: $14,946; $24,586; $21,746 (total ~$61,278).
• Shares acquired via conversion: 2,702; shares withheld/disposed for taxes: 820; net issued to insider: 1,882.
• Shares owned after transaction: not specified in the filing.
• Footnotes: F1–F4 indicate (1) each RSU converts to one share and (2–4) vesting schedules: the issued shares are part of multi-year installments beginning on Feb 13, 2026; Feb 14, 2024; and Feb 16, 2023 respectively.
• Timeliness: Filing date was Feb 18, 2026. Transactions on Feb 14 and Feb 16 appear to be reported within the two-business-day window; the Feb 13 transaction may be outside that window by one business day (the filing does not mark a late filing explicitly in the summary provided).

Context

• This is a routine compensation event: RSUs vested/converted and shares were withheld to cover tax liabilities (code F). Withholding is not the same as an open-market sale and typically reflects tax obligations rather than a decision to liquidate holdings. For retail investors, these filings show insider compensation flows but do not necessarily indicate a buy/sell signal.